Pages that link to "Item:Q4665957"
From MaRDI portal
The following pages link to A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials (Q4665957):
Displaying 36 items.
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs (Q70261) (← links)
- On generalized multinomial models and joint percentile estimation (Q393556) (← links)
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
- Design efficiency in dose finding studies (Q956828) (← links)
- Simulation-based sequential Bayesian design (Q997303) (← links)
- Optimization in a multivariate generalized linear model situation (Q1023815) (← links)
- Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials (Q1654244) (← links)
- Optimal designs and limiting optimal designs for a trinomial response (Q1888873) (← links)
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials (Q2320854) (← links)
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
- Adaptive designs for dose-finding based on efficacy-toxicity response (Q2492921) (← links)
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes (Q2861956) (← links)
- Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion (Q2893431) (← links)
- Sequential Methods in Multi-Arm Clinical Trials (Q3068083) (← links)
- Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials (Q3078842) (← links)
- Adaptive Decision Making in a Lymphocyte Infusion Trial (Q3078989) (← links)
- Directed Walk Designs for Dose-Response Problems with Competing Failure Modes (Q3079102) (← links)
- Dose-Finding with Two Agents in Phase I Oncology Trials (Q3079137) (← links)
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design (Q4796210) (← links)
- Optimal sampling for repeated binary measurements (Q4818488) (← links)
- (Q5072154) (← links)
- Simple benchmark for complex dose finding studies (Q5170208) (← links)
- Up-and-Down Designs for Selecting the Dose with Maximum Success Probability (Q5458029) (← links)
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent (Q5714615) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
- Combined criteria for dose optimisation in early phase clinical trials (Q6625215) (← links)
- A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)
- Rejoinder: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629390) (← links)
- Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression (Q6629418) (← links)
